Abstracts/Presentations
Urinary NMP22 Plus Cytology: Diagnostic Synergy for Detecting Urothelial Carcinoma.
Mansoor, I. National Academy of Clinical Biochemistry 2004. Los Angeles, CA 2004.

Non-invasive Screening of Urinary Bladder Cancer: Is NMP22® BladderChek® Paving the Avenue?
Oehr, P., AUA 99th Annual Meeting, San Francisco, California, 2004.

The Role of Nuclear Matrix Proteins in Cancer Diagnosis.

Watkins, BA., Hartshorn C. Amer Clinl Lab, 18:28-29, 1999.

A Comparative Study of Telomerase, BTA, NMP22, and Urinary Cytology in Bladder Tumor.
Lee, S-J., Lee, W-I., Chang, S-G., Lee, C-H., Kim, JI. AUA 94th Annual Meeting, Dallas, Texas, 1999.

Comparison of the Monoclonal UBC-ELISA Test and the NMP22 ELISA Test for the Detection of Transitional Cell Cancer of the Bladder.
Mian, C., Pycha, A., Lodde, M., Haitel, A., Vigl, EE., Marberger, M. Vienna, Austria. AUA 94th Annual Meeting, Dallas, Texas, 1999.

Office BTA Stat Versus Laboratory BTA TRAK and NMP22 Test: Comparison Study.
Agarwal, A., Sharma, S., Nelson, D., Zippe, C. Cleveland Clinic Foundation, Cleveland, OH. AUA 94th Annual Meeting, Dallas, Texas, 1999.

Role of NMP22 as a Novel Tumor Marker for Early Detection and Monitoring Treatment of Bladder Cancer.
Zippe, C.D., Pandrangi, L.V., Agarwal, A. Cleveland Clinic Foundation, Cleveland, OH. XIIIth Congress of the European Association of Urology, Barcelona, Spain, 1998.

A Comparison of the Sensitivity, Specificity and Cost of NMP22, BTA, STAT and Voided Urine Cytology for the Detection of Bladder Cancer.
Santiago, L., Huang, S., Rhee, E., Kaswick, J. Kaiser Permanente, Los Angeles, CA. NCI-Organ Site Program—Bladder Cancer: New Concepts in Biology and Therapy, 1998. Seventh European Urological Winter Forum, Davos, Switzerland, 1998.

Differential Nuclear Matrix Protein Expression in Prostate Cancers: Correlation with Pathologic Stage.
Lakshmanan, Y., Subong, ENP., Partin, A.W. James Buchanan Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland. J Urology, 159:1354-1358, 1998.

Urinary Nuclear Matrix Protein 22 (NMP22) as a Marker for Screening Urothelial Cancer in Patients with Microscopic Hematuria.
Miyanaga, N., Akaza, H., Tsukamoto, T., Ishakawa, S., Noguchi, R., Ohtani, M., Kawabe, K., Kubota, Y., Fujita, K., Obata, K., Hirao, Y., Kotake, T., Ohmori, H., Kumazawa, J., Koiso, K. Japan. J Urology, 159(5):243, Supplement, 1998.

Nuclear Matrix Protein 22 (NMP22): A Tumor Marker in Primary Diagnosis and Follow up of Bladder Cancer.
Lükecke, G., Farkas, P., Edler, M., Kraus, S., Miller, J., Fischer, C., Weidner, W. Giessen, Germany. J Urology, 159(5):244, Supplement, 1998.

Sensitivity and Specificity of NMP22, Telomerase, and BTA in the Detection of Human Bladder Cancer.
Landman, J., Kavaler, E., Chang, Y., Droller, M.J., Liu, BC-S. New York, NY. J Urology, 159(5):245, Supplement, 1998.

Prospective, Multi-Center Study of NMP22 and Cytology in Patients with Hematuria.
Carpinito,* G.A., Rukstalisa, D.B., Pandrangib, LV., Agarwalb, A., Novickb, A.C., Zippeb, C.D. (*Boston, MA, aPhiladelphia, PA, bCleveland, OH). J Urology, 159(5):245, Supplement, 1998.

Detection of Bladder Cancer Using a New Quantitative Urinary Tumor Marker –BTA TRAK.
Heicappell, R., Wettig, I., Hardung, R., Fu, S., Steiner, U., Müller, M., Miller, K. Freie Universität, Berlin, Germany. Eur Urol, 33:1-191, Supplement 1, 1998.

Evaluation of Nuclear Matrix Protein (NMP22) as a Diagnostic Marker for Superficial Bladder Cancer.
Del Nero, A., Esposito, N., Montanari, E., Currò, A., Mangiarotti, B., Trinchieri, A., Zanetti, G., Biasoni, D., Pisani, E. Institute of Urology, IRCCS Ospedale Maggiore di Milano, Milan, Italy. Eur Urol, 33:1-191, Supplement 1, 1998.

Nuclear Matrix Protein 22 in Urine as a Tumour Marker in Patients with Transitional Cell Carcinoma?
Doehn, C., Bäumgartel, M., Jocham, D., Böhle, A. Medical University of Lübeck, Germany. Eur Urol, 33:1- 191, Supplement 1, 1998.

NMP22: A Sensitive Urinary Tumor Marker in the Detection of Transitional Cell Carcinoma of the Bladder.
Kaswick, J., Rhee, E., Patel, H., Kurzner, P., Loo, R., Vandergast, T., Stout, L., Bellman, G. Kaiser Permanente Medical Center, Los Angeles, California. Eur Urol, 33:1–191, Supplement 1, 1998.

Role of NMP-22 as a Novel Tumor Marker for Early Detection and Monitoring Treatment of Bladder Cancer.
Zippe, C.D., Pandrangi, LV., Agarwal, A. The Cleveland Clinic Foundation, Cleveland, Ohio. Eur Urol, 33:1–191, Supplement 1, 1998.

Clinical Application of NMP22 and Cytology in Patients with Hematuria.
Carpinito, G.A., Fingliss, M. Eur Urol, 33:1–191, Supplement 1, 1998.

Role of NMP22 as a Novel Tumor Marker for Early Detection and Monitoring Treatment of Bladder Cancer.
Zippe, C.D., Pandrangi, L.V., Agarwal, A. Cleveland Clinic Foundation, Cleveland, OH. Ninth International Hamburg Symposium, 1997.

Nuclear Matrix Protein 22 (NMP22): A Powerful Urine Marker in Tumor Screening and Follow up in Bladder Cancer.
Ludecke, G., Edler, M., Miller, J., Fischer, C., Kraus, S., Weidner, W. Giessen, Germany. AUA 93rd Annual Meeting San Diego, CA, 1998. Ninth International Hamburg Symposium, 1997.

Prospective Comparison of the Sensitivity and Specificity of NMP22™ and Voided Urine Cytology in the Diagnosis of Transitional Cell Carcinoma of the Bladder.
Rukstalis, DB., Ruyle, SA., Coll. ME., Hander, JJ., Edmonds, P. Medical College of Pennsylvania, Philadelphia, PA. AUA 55th Annual Mid-Atlantic Section, 1997.

NMP22™: A Sensitive Urinary Tumor Marker in the Detection of Transitional Cell Carcinoma of the Bladder.
Rhee, E.Y., Patel, H., Kurzner, P., Loo, R., Bellman, G., Vandergast, T., Stout, L., Kaswick, J. Southern California Kaiser Permanente Medical Group, Los Angeles, CA. AUA 73rd Annual Western Section, 1997.

Clinical Application of NMP22 Levels for the Early Detection of Bladder Cancer.
Carpinito, G.A., Fingliss, M. Boston University Medical Center, Boston, MA. AUA 66th Annual Meeting, 1997. Sixth European Urological Winter Forum, Davos, Switzerland, 1997.

Determination De NMP22.
Caballero, J.M., Alsina, M., Barrat, P., Bastus, R., Risto, J. Servicio de Urologia, Hospital Mutual de Terrasssa, Barcelona, Spain. Actas Urologiacas Espanolas- National Congress, 1997.

Evaluation of Urinary Nuclear Matrix Protein (NMP22) as a Potential Screening Marker for Transitional Cell Carcinoma of the Urinary Tract.
Landman, J., Droller, M.J., Liu, BC-S. Mt. Sinai Medical Center, New York, NY. The Sixth European Urological Winter Forum, Davos, Switzerland, 1997.

NMP22™: A New Marker for Bladder Cancer.
Malpassi, P., Boscaro, A., Zacchini, A., Sproviere, G., Reggiani, A., Ligabue A. Bologna, Italy. Biochimica clinica, 21:7-8, 1997.

Posters
Prospective Evaluation of Cytology and NMP22 in the Evaluation of Patients with Suspicion or History of Bladder Cancer.
Carpinito, G.A., Fingliss, M. XIIIth Congress of the European Association of Urology, Barcelona, Spain, 1998.

Clinical Application of NMP22 and Cytology in Patients with Hematuria.
Carpinito, G.A., Fingliss, M. XIIIth Congress of the European Association of Urology, Barcelona, Spain, 1998.

Prospective, Multi-Center Study of NMP22 and Cytology in Patients with Hematuria.
Carpinito,* G.A., Zippeb, C.D., Pandrangia, L.V., Agarwalb, A., Novickb, A.C., Rukstalisa, D.B. (*Boston, MA, aCleveland, OH, bPhiladelphia, PA.) AUA 93rd Annual Meeting, San Diego, CA, 1998.

A Comparison of The Sensitivity, Specificity and Cost of NMP22, BTA STAT and Voided Urine Cytology for the Detection of Bladder Cancer.
Santiago, L., Huang, S., Rhee, E., Kaswick, J. Kaiser Permanente, Los Angeles, CA. Seventh European Urological Winter Forum, Davos, Switzerland, 1998.

The Use of NMP22 and Cytology in the Management of Patients at Risk for Transitional Cell Carcinoma (TCC).
Sawczuk, I.S. Columbia Presbyterian Medical Center, New York, NY. NCI-Organ Site Program – Bladder Cancer: New Concepts in Biology and Therapy, 1998.

Nuclear Matrix Protein 22 in Urine as a Tumor Marker in Patients with Transitional Cell Carcinoma of the Bladder?
Doehn, C., Baumgärtel, M., Jocham, D., Böhle, A. Medical University of Lübeck, Lübeck, Germany. XIII Congress of the European Association of Urology, Barcelona, Spain, 1998.

NMP22™: A Sensitive Urinary Tumor Marker in the Detection of Superficial Bladder Cancer.
Rhee, E.Y., Patel, H., Kurzner, P., Loo, R., Bellman, G., Vandergast, T., Stout, L., Kaswick, J. Southern California Kaiser Permanente Medical Group, Los Angeles, CA. AUA 73rd Annual Western Section, 1997. Sixth European Urological Winter Forum, Davos, Switzerland, 1997.

Evaluation of NMP22 in the Detection of Recurrent Transitional Cell Carcinoma of the Bladder.
Stampfer, D.A., Carpinito, G.A., Rodriguez-Villanueva, J., Willsey, L.W., Dinney, C.P., Grossman, H.B., Fritsche, H.A., McDougal, W.S. AUA 66th Annual Meeting of the New England Section, 1997. Sixth European Urological Winter Forum, Davos, Switzerland, 1997.

Clinical Application of NMP22 Levels for the Early Detection of Bladder Cancer.
Carpinito, G.A., Fingliss, M. Boston University Medical Center, Boston, MA. AUA 66th Annual Meeting of the New England Section, 1997. Sixth European Urological Winter Forum, Davos, Switzerland, 1997.

The NMP22 Prospective Clinical Trial: Follow-up of Subjects with No Evidence of Disease (NED).
Carpinito, G.A., and NMP22 Study Group. XII Congress of the European Association of Urology, Paris, France, 1996.

The NMP22 Test Kit in the Management of Patients with TCC.
Soloway, M., and the NMP22 Study Group. XII Congress of the European Association of Urology, Paris, France, 1996.

NMP22™ in the Management of Patients with Transitional Cell Carcinoma of the Urinary Tract (TCC).
Messing, E.M., and NMP22 Multi-Center Study Group, University of Rochester, Rochester, NY. International Bladder Symposium, Boston, MA, 1996.

Evaluation of the NMP22 Immunoassay in the Detection of Transitional Cell Carcinoma (TCC) of the Urinary Tract.
Rodriguez-Villanueva, J., Dinney, C.P.N., Grossman, H.B., Fritsche, H.A., Houston, TX.